231 Gemcitabine (GEM)-cisplatin (CDDP)-vinorelbine (VNR) combination in advanced non-small-cell lung cancer (NSCLC). A phase II randomized studyP. Comella, G. Comella, Luigi Manzione et al.|Lung Cancer|1997Cited by 7
Cisplatin-gemcitabine-vinorelbine (PGV) vs cisplatin-vinorelbine (PV) vs cisplatin-gemcitabine (PG) in advanced non-small cell lung cancer (NSCLC). Interim analysis of a SICOG phase III trialP. Comella, G. Comella, N. Panza et al.|European Journal of Cancer|1999Cited by 3
Cisplatin — gemcitabine — paclitaxel (PGT) in the treatment of advanced non-small-cell lung cancer (NSCLC). A southern Italy cooperative oncology group (SICOG) phase II studyG. Frasci, G. Comella, P. Comella et al.|European Journal of Cancer|1999Cited by 3
Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER2-positive metastatic breast cancerGiulio Metro, F. Cognetti, Alessandra Fabi et al.|Journal of Clinical Oncology|2008Cited by 3
Gemcitabine (GEM) — Cisplatin (COOP) — Vinorelbine (VNR) combination in advanced non-small-cell lung cancer (NSCLC). A phase II randomized studyP. Comella, G. Comella, N. Panza et al.|European Journal of Cancer|1997Cited by 1